CIK 0001501796 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Aura Biosciences, Inc.
Sign in to watch- Ticker
- AURA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 320271970
- Phone
- (617)500-8864
- Business address
- 80 GUEST STREET, BOSTON, MA, 02135
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-11 | Mattessich Antony C. Director | Grant or award | +15,000 | 38,500 | ||
| 2026-06-11 | Mattessich Antony C. Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2026-05-19 | Holles Natalie C. See Remarks | Grant or award | +600,118 | 600,118 | ||
| 2026-05-19 | Holles Natalie C. See Remarks | Grant or award | +553,844 | 1,153,962 | ||
| 2026-05-19 | Holles Natalie C. See Remarks | Grant or award · Stock Option (Right to Buy) | +2,169,103 | 2,169,103 | ||
| 2026-05-07 | Matrix Capital Management Company, LP 10% owner | Sale | −6,922,870 | $5.64 | $39.0M | 0 |
| 2026-04-16 | Kilroy Conor See Remarks | Sale | −11,738 | $7.02 | $82K | 217,835 |
| 2026-03-02 | Kilroy Conor See Remarks | Grant or award | +62,339 | 229,573 | ||
| 2026-03-02 | Kilroy Conor See Remarks | Grant or award · Stock Option (Right to Buy) | +112,661 | 112,661 | ||
| 2026-03-02 | Gibney Anthony S See Remarks | Grant or award | +71,245 | 278,178 | ||
| 2026-03-02 | Gibney Anthony S See Remarks | Grant or award · Stock Option (Right to Buy) | +128,755 | 128,755 | ||
| 2026-03-02 | de los Pinos Elisabet See Remarks | Grant or award | +166,000 | 575,815 | ||
| 2026-03-02 | de los Pinos Elisabet See Remarks | Grant or award · Stock Option (Right to Buy) | +249,000 | 249,000 | ||
| 2026-03-02 | Plavsic Mark Chief Technology Officer | Grant or award | +62,339 | 243,736 | ||
| 2026-03-02 | Plavsic Mark Chief Technology Officer | Grant or award · Stock Option (Right to Buy) | +112,661 | 112,661 | ||
| 2026-03-02 | Hopkins Janet Jill Chief Medical Officer | Grant or award | +89,056 | 321,340 | ||
| 2026-03-02 | Hopkins Janet Jill Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +160,944 | 160,944 | ||
| 2026-03-02 | Elazzouzi Amy Senior Vice President, Finance | Grant or award | +44,528 | 120,060 | ||
| 2026-03-02 | Elazzouzi Amy Senior Vice President, Finance | Grant or award · Stock Option (Right to Buy) | +80,472 | 80,472 | ||
| 2026-02-17 | Kilroy Conor See Remarks | Sale | −12,079 | $5.05 | $61K | 167,234 |
Page 2 of 11 · 219 trades